Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn’s disease: A Case Series.

Related Articles Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn’s disease: A Case Series. Am J Gastroenterol. 2018 Apr;113(4):627-629 Authors: Park S, Evans E, Sandborn WJ, Boland B PMID: 29610516 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29610516?dopt=Abstract

Read More

Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn’s Disease Patients Independent of Inflammation Recurrence.

Related Articles Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn’s Disease Patients Independent of Inflammation Recurrence. Am J Gastroenterol. 2018 Apr;113(4):576-583 Authors: Gajendran M, Bauer AJ, Buchholz BM, Watson AR, Koutroubakis IE, Hashash JG, Ramos-Rivers C, Shah N, Lee KK, Cruz RJ, Regueiro M, Zuckerbraun B, Schwartz M, Swoger J, Barrie A, Harrison J, Hartman DJ, Salgado J, Rivers WM, Click B, Anderson AM, Umapathy C, Babichenko D, Dunn MA, Binion DG Abstract OBJECTIVES: Anastomotic reconstruction following intestinal resection in Crohn’s…

Read More

ACG Clinical Guideline: Management of Crohn’s Disease in Adults.

Related Articles ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018 Apr;113(4):481-517 Authors: Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE Abstract Crohn’s disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn’s disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn’s disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology…

Read More

Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD.

Past Time for Doctors to Lessen their Dependence on Corticosteroids in the Treatment of IBD. Am J Gastroenterol. 2018 Mar;113(3):418-420 Authors: Bernstein CN Abstract Corticosteroids and antibodies to tumor necrosis factor (anti-TNF) are mainstays of treatment of acutely active IBD and while anti-TNF therapy is indicated for maintenance therapy, chronic corticosteroid therapy is associated with known significant risks. Nonetheless, chronic or recurrent corticosteroid treatment in IBD is common. In this edition of the journal Lewis et al. use Medicaid and Medicare databases to contrast adverse outcomes in persons with IBD…

Read More

Continuing Medical Education Questions: March 2018: Long-Term Safety of In Utero Exposure to Anti-TNF╬▒ Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.

Continuing Medical Education Questions: March 2018: Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018 Mar;113(3):404 Authors: Veerappan GR PMID: 29535439 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29535439?dopt=Abstract

Read More

Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study.

Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am J Gastroenterol. 2018 Mar 13;: Authors: Jensen CB, Ängquist LH, Mendall MA, Sørensen TIA, Baker JL, Jess T Abstract BACKGROUND: The increasing incidence of inflammatory bowel disease (IBD) in western countries has led to the hypothesis that obesity-related inflammation could play a role in the etiology of IBD. However, this hypothesis lacks confirmation in studies of individuals prior to the typical onset of IBD in young adulthood. METHODS: In a cohort of 316,799…

Read More

Identification of Individuals with Functional Dyspepsia With a Simple, Minimally Invasive Test: A Single Center Cohort Study of the Oral Capsaicin Test.

Identification of Individuals with Functional Dyspepsia With a Simple, Minimally Invasive Test: A Single Center Cohort Study of the Oral Capsaicin Test. Am J Gastroenterol. 2018 Mar 13;: Authors: Hammer J Abstract OBJECTIVES: The diagnosis of functional dyspepsia (FD) is challenging due to the lack of reliable biological markers to support the diagnosis. We assessed the relevance of a previously validated simple test for chemical hypersensitivity in the setting of a gastrointestinal outpatient department. METHODS: A total of 224 outpatients who were referred for evaluation of gastrointestinal symptoms in the…

Read More
<< Go Back